F2G Ltd Completes $30 Million Financing Round to Fund Pre-clinical and Clinical Development of Novel Anti-fungal Compounds. Manchester, UK, Sept 5th 2012 - F2G Limited, an antifungal drug discovery ...

MANCHESTER, United Kingdom, Sept. 12, 2024 (GLOBE NEWSWIRE) -- F2G Ltd, a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat life-threatening ...

MANCHESTER, United Kingdom, June 18, 2025 (GLOBE NEWSWIRE) -- F2G Ltd, a clinical-stage biopharmaceutical company developing olorofim, a novel therapy to treat life-threatening rare fungal infections ...

F2G has discovered and is developing the orotomides, a novel class of antifungal agents. The orotomides act via a different mechanism than currently marketed antifungal agents and are active against ...

F2G has raised $60.8 million to fund late-phase clinical development of its antifungal agent olorofim and prepare for commercialization. The Cowen Healthcare Investments-led round comes four years ...

Shionogi and F2G have partnered to develop and commercialise the new antifungal agent olorofim – formerly F901318 – for invasive fungal infections in Europe and Asia. F2G developed olorofim as a novel ...

MANCHESTER, UK, 4 August 2022 – F2G Ltd, a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat life-threatening rare fungal infections with a ...

(Reuters) - F2G said on Thursday it has raised $100 million from investors including AMR Action Fund, backed by large drugmakers such as Johnson & Johnson and Pfizer, to help it develop treatments for ...

- Brings substantial pharmaceutical expertise to lead the development and commercialization of olorofim in the USA - Ian Nicholson stepping down to pursue non-executive roles MANCHESTER, England and ...

F2G’s attempt to end a two-decade drought in novel therapies for invasive fungal infections has hit a hurdle after the FDA said it was unable to approve its olorofim candidate. The US regulator sent a ...

NORTH West biotech company F2G has raised $30m (£18.8m) in an institutional fund-raising. F2G, based in Eccles, is a pioneer in discovering and developing drugs to treat life threatening fungal ...

Data reinforce olorofim's potential as a first-in-class treatment for patients with invasive fungal diseases and limited or no antifungal treatment options MANCHESTER, United Kingdom, June 18, 2025 ...